CyPath Lung Expansion to Post-Treatment Monitoring Fuels 55% Surge
BIAF has more than doubled off its 52-week low of $4.56 on elevated volume (17× avg).
Summary
Shares jumped 54.78% to $10.20 on Wednesday after the company announced Tuesday that CyPath Lung is being positioned for post-curative surveillance to monitor lung cancer recurrence. This expands the test's addressable market beyond initial risk assessment, allowing physicians to use it alongside routine imaging when new pulmonary nodules appear. The move builds on an Aug. 18 federal distribution agreement with AvMEDICAL covering VA hospitals and military medical systems. The 1-for-15 reverse split on Aug. 24 cut the float to roughly 592,373 shares, amplifying the price move. Q2 results showed 216% test volume growth but also a going concern warning and cash runway ending this month, so the rally is driven by the new indication rather than financial strength.
At the time of this announcement, BIAF was trading at $9.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $4.56 to $202.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.